Lung cancer drug combo tested before surgery shows promise, but study halted early
NCT ID NCT04832854
First seen Mar 19, 2026 · Last updated Jun 16, 2026 · Updated 18 times
Summary
This study tested a combination of two immunotherapy drugs (tiragolumab and atezolizumab) given before and after surgery for people with early-stage non-small cell lung cancer. The goal was to see if the treatment was safe and helped shrink tumors before surgery. The study was terminated early, but results may still provide useful information about how well the drugs work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Columbia University
New York, New York, 10032-3725, United States
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, 15006, Spain
-
Corporacio Sanitaria Parc Tauli
Sabadell, Barcelona, 08208, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, 28222, Spain
-
ICO L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Kantonsspital Baden
Baden, 5404, Switzerland
-
Kantonsspital Graubünden Medizin Onkologie
Chur, 7000, Switzerland
-
Kantonsspital St. Gallen
Sankt Gallen, 9007, Switzerland
-
Kantonsspital Winterthur
Winterthur, 8401, Switzerland
-
NYU Cancer Center
New York, New York, 10016, United States
-
Peter Maccallum Cancer Institute
Melbourne, Victoria, 3000, Australia
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
St. Vincent's Hospital
Gyeonggi-do, 16247, South Korea
-
Sunshine Coast University Hospital
Birtinya, Queensland, 4575, Australia
-
University of Southern California
Los Angeles, California, 90033, United States
-
UniversitätsSpital Zürich
Zurich, 8091, Switzerland
-
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035, Spain
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Winthrop Univ Hospital
Mineola, New York, 11501, United States
Conditions
Explore the condition pages connected to this study.